Navigation Links
Acclarent, Inc. Completes Office-Based Study Using Balloon Sinuplasty(TM) Technology

MENLO PARK, Calif., June 25 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing, and commercializing products that address conditions affecting the ear, nose and throat (ENT) today announced the completion of a study evaluating the treatment of patients with Balloon Sinuplasty(TM) technology in the office setting. The prospective, multi-center comparative study evaluated the safety, effectiveness, and cost of performing sinus surgery in the office versus in a hospital operating room setting.

"We are very pleased to have completed this study demonstrating that physicians can successfully treat patients in the office setting using our enabling technology," said Bill Facteau, President and CEO of Acclarent. "We look forward to partnering with physicians in delivering quality, cost-effective healthcare in the office, which offers the potential for significant savings for our healthcare system."

About Acclarent

Acclarent is a global medical technology company dedicated to the development of innovative products to further meet the needs of ENT surgeons and their patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. With the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel technologies in all areas of ENT. Acclarent markets and sells its products worldwide and our technology has been used by thousands of physicians.

For more information about Acclarent, visit

SOURCE Acclarent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Acclarent, Inc. Closes $26 Million Financing
2. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
3. Acclarent, Inc. Awarded Red Herring 100 North America
4. Eligard(R) six-month formulation successfully completes European approval procedure
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
8. GSI Securitization Completes Merger and Domicile Transfer
9. Medical Services International Inc. Completes Testing for European Union (EU) Application
10. Inverness Completes Acquisition of Cholestech
11. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... California-based ... 15 years, announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks ... 45 years, FHC was awarded the largest Affordable Care Act grant for Federally ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell of Peconic ... on Long Island’s east end. During the broadcast, entitled “Eyes: the Window to the ... glaucoma and cataracts, and how a visit with his grandmother to her physician put ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb ... the leading plastic surgery practices in Florida, is proud to announce that Dr. ... surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Vasont ... their Vasont Universal Integrator (VUI) extension unites with Syncro Soft’s latest software update, ... as a continuous process with the latest release of oXygen® XML editor and ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
(Date:11/30/2015)... --> --> ... by Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application ... Geography - Global Forecast to 2020", published by MarketsandMarkets, is ... CAGR of 5.2% during the forecast period from 2015 to ... 62 Figures spread through 167 P ages and in-depth ...
(Date:11/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... development of oral drug delivery systems, announced today it ... to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT") ... ORMD-0801, in China , ... . The agreements were signed at the Israel Knesset ...
Breaking Medicine Technology: